These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10980848)

  • 1. Effect of lipid-lowering therapy on vasomotion and endothelial function.
    Kinlay S; Plutzky J
    Curr Cardiol Rep; 1999 Sep; 1(3):238-43. PubMed ID: 10980848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid lowering improves endothelial functions.
    Libby P; Aikawa M; Kinlay S; Selwyn A; Ganz P
    Int J Cardiol; 2000 Jun; 74 Suppl 1():S3-S10. PubMed ID: 10856767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
    Laufs U
    Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points.
    Kinlay S; Selwyn AP; Delagrange D; Creager MA; Libby P; Ganz P
    Curr Opin Lipidol; 1996 Dec; 7(6):389-97. PubMed ID: 9117144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-lipid-lowering effects of statins on atherosclerosis.
    Rosenson RS
    Curr Cardiol Rep; 1999 Sep; 1(3):225-32. PubMed ID: 10980846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits.
    Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M
    Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy.
    van Boven AJ; Jukema JW; Paoletti R
    Pharmacol Res; 1994 Apr; 29(3):261-72. PubMed ID: 8058597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?
    Sessa WC
    Trends Mol Med; 2001 May; 7(5):189-91. PubMed ID: 11325618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndromes.
    Adams MR; Kinlay S; Blake GJ; Orford JL; Ganz P; Selwyn AP
    Annu Rev Med; 2000; 51():149-67. PubMed ID: 10774458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of endothelial dysfunction in coronary artery disease and implications for therapy.
    Kinlay S; Ganz P
    Am J Cardiol; 1997 Nov; 80(9A):11I-16I. PubMed ID: 9375937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial function as an end-point in interventional trials: concepts, methods and current data.
    Lüscher TF; Noll G
    J Hypertens Suppl; 1996 Sep; 14(2):S111-9; discussion S119-21. PubMed ID: 8934387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol lowering and the vessel wall: new insights and future perspectives.
    Stulc T; Ceska R
    Physiol Res; 2001; 50(5):461-71. PubMed ID: 11702850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic trials of lipid-lowering therapy: an update.
    Mancini GB
    Curr Opin Lipidol; 1995 Dec; 6(6):379-85. PubMed ID: 8750252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Wieland H
    Herz; 2000 Mar; 25(2):117-25. PubMed ID: 10829251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis.
    Ganz P; Creager MA; Fang JC; McConnell MV; Lee RT; Libby P; Selwyn AP
    Am J Med; 1996 Oct; 101(4A):4A10S-16S. PubMed ID: 8900332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of statins in acute coronary syndromes: the mechanisms behind the outcomes.
    Plana JC; Jones PH
    Curr Atheroscler Rep; 2001 Sep; 3(5):355-64. PubMed ID: 11487446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of nitric oxide in cardiovascular disease: focus on the endothelium.
    Cannon RO
    Clin Chem; 1998 Aug; 44(8 Pt 2):1809-19. PubMed ID: 9702990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelium-dependent effects of statins.
    Wolfrum S; Jensen KS; Liao JK
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):729-36. PubMed ID: 12615672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid lowering agents and the endothelium: an update after 4 years.
    Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2012 Jan; 10(1):33-41. PubMed ID: 22112353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.